Zelira Therapeutics Ltd
ASX:ZLD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Zelira Therapeutics Ltd
ASX:ZLD
|
AU |
|
B
|
Botnia Exploration Holding AB (publ)
STO:BOTX
|
SE |
|
I
|
IberAmerican Lithium Corp
OTC:IBRLF
|
CA |
|
A
|
Activation Group Holdings Ltd
HKEX:9919
|
CN |
|
L
|
Lottomatica Group SpA
MIL:LTMC
|
IT |
|
Sensus Healthcare Inc
NASDAQ:SRTS
|
US |
|
Herbalife Nutrition Ltd
NYSE:HLF
|
KY |
|
ChinaLin Securities Co Ltd
SZSE:002945
|
CN |
|
Infinite Group Inc
OTC:IMCI
|
US |
|
N
|
Nature Wood Group Ltd
NASDAQ:NWGL
|
MO |
|
H
|
Hyperdynamics Corp
OTC:HDYNQ
|
US |
|
Champion Pacific Indonesia Tbk PT
IDX:IGAR
|
ID |
Zelira Therapeutics Ltd
Zelira Therapeutics Ltd. is a bio-pharmaceutical company. The company is headquartered in Perth, Western Australia. The company went IPO on 2003-07-28. The firm is focused on developing and clinically validating branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its prescription (Rx) business, including insomnia, autism and chronic non-cancer pain. The firm's lead product, Zenivol, is a cannabinoid-based medicine for the treatment of chronic insomnia. The firm is engaged in human clinical trial programs focused on insomnia, autism and opioid reduction with activities in Australia and the United States. The company is also focused on pre-clinical research examining the effects of cannabinoids in breast, brain and pancreatic cancer, as well as research and development of cannabinoids to treat diabetes-associated cognitive decline. Its SprinjeneCBD toothpaste product is a hemp-derived, oral care product containing cannabinoids and based on the patented technology of blackseed oil and zinc.
Zelira Therapeutics Ltd. is a bio-pharmaceutical company. The company is headquartered in Perth, Western Australia. The company went IPO on 2003-07-28. The firm is focused on developing and clinically validating branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its prescription (Rx) business, including insomnia, autism and chronic non-cancer pain. The firm's lead product, Zenivol, is a cannabinoid-based medicine for the treatment of chronic insomnia. The firm is engaged in human clinical trial programs focused on insomnia, autism and opioid reduction with activities in Australia and the United States. The company is also focused on pre-clinical research examining the effects of cannabinoids in breast, brain and pancreatic cancer, as well as research and development of cannabinoids to treat diabetes-associated cognitive decline. Its SprinjeneCBD toothpaste product is a hemp-derived, oral care product containing cannabinoids and based on the patented technology of blackseed oil and zinc.
